Key financial metrics to focus on from the earnings conference call transcripts are:
1. Total Revenue: In the fourth quarter of 2016, the company reported $326 million in total revenue, comprised of product revenue, royalties, and contract revenue. For the full year, the total revenue was $1.1 billion.

2. Cost of Product Revenue: The cost of product revenue for the quarter and full year was $20 million and $58 million, respectively.

3. Research and Development (R&D) Expense: R&D expense for the quarter was $162 million, including non-cash stock compensation. The full year R&D expense was $582 million, including non-cash stock compensation. In 2017, the ongoing R&D expense is expected to be in the range of $785 million to $835 million, including non-cash expenses related to employee equity awards.

4. Selling, General, and Administrative (SG&A) Expense: SG&A expense for the quarter was $96 million, including non-cash stock compensation. For the full year, the SG&A expense was $303 million, including non-cash stock compensation. In 2017, the SG&A expense is expected to be in the range of $340 million to $360 million, including non-cash expenses related to employee equity awards.

5. Net Income: The company reported net income of $9 million for the quarter and $104 million for the full year. The expected net income for 2017 is in the range of $50 million to $70 million. However, the achievement and timing of milestones may create variability in net income on a quarterly basis.

6. Cash and Marketable Securities: The company ended the fourth quarter with $809 million in cash and marketable securities, and they anticipate continued growth in their cash position.

7. Milestone Payments: The company anticipates receiving up to $300 million in milestone payments from collaboration partners in 2017, with significant portions expected from Lilly for baricitinib approvals in the U.S. and Europe.

These key financial metrics provide insight into the company's revenue sources, expenses, and expected earnings for 2017.